GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALGEN - FR0004053510 - Common Stock

2.56 EUR

+0.03 (+1.19%)

Last: 1/22/2026, 7:00:00 PM

Fundamental Rating

Overall ALGEN gets a fundamental rating of 4 out of 10. We evaluated ALGEN against 86 industry peers in the Biotechnology industry. Both the profitability and the financial health of ALGEN get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, ALGEN is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALGEN was profitable.
In the past year ALGEN has reported a negative cash flow from operations.
In multiple years ALGEN reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.

1.2 Ratios

ALGEN has a Return On Assets of 3.31%. This is amongst the best in the industry. ALGEN outperforms 81.40% of its industry peers.
With an excellent Return On Equity value of 7.00%, ALGEN belongs to the best of the industry, outperforming 80.23% of the companies in the same industry.
The Return On Invested Capital of ALGEN (3.17%) is better than 75.58% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ALGEN is significantly below the industry average of 11.58%.

		Industry Rank	Sector Rank
ROA	3.31%
ROE	7%
ROIC	3.17%

ROA(3y)4.35%

ROA(5y)1.91%

ROE(3y)7.98%

ROE(5y)2.79%

ROIC(3y)5.56%

ROIC(5y)N/A

1.3 Margins

The Profit Margin of ALGEN (6.14%) is better than 80.23% of its industry peers.
Looking at the Operating Margin, with a value of 5.97%, ALGEN is in the better half of the industry, outperforming 75.58% of the companies in the same industry.
ALGEN has a better Gross Margin (94.91%) than 91.86% of its industry peers.
ALGEN's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	5.97%
PM (TTM)	6.14%
GM	94.91%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.73%

GM growth 5Y0.4%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ALGEN has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALGEN has more shares outstanding
ALGEN has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.77, we must say that ALGEN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.77, ALGEN is in the better half of the industry, outperforming 67.44% of the companies in the same industry.
A Debt/Equity ratio of 0.71 indicates that ALGEN is somewhat dependend on debt financing.
ALGEN's Debt to Equity ratio of 0.71 is in line compared to the rest of the industry. ALGEN outperforms 50.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.71
Debt/FCF	N/A
Altman-Z	1.77

ROIC/WACC0.43

WACC7.33%

2.3 Liquidity

ALGEN has a Current Ratio of 2.41. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.41, ALGEN perfoms like the industry average, outperforming 51.16% of the companies in the same industry.
ALGEN has a Quick Ratio of 2.21. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
ALGEN has a Quick ratio (2.21) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.41
Quick Ratio	2.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.46%.
Looking at the last year, ALGEN shows a decrease in Revenue. The Revenue has decreased by -2.21% in the last year.
ALGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.46% yearly.

EPS 1Y (TTM)5.46%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-76.91%

Revenue 1Y (TTM)-2.21%

Revenue growth 3Y16.31%

Revenue growth 5Y18.46%

Sales Q2Q%-10.34%

3.2 Future

ALGEN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by 0.00% yearly.
ALGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.37% yearly.

EPS Next Y-100%

EPS Next 2Y-41.42%

EPS Next 3Y0%

EPS Next 5YN/A

Revenue Next Year-7.14%

Revenue Next 2Y3.51%

Revenue Next 3Y10.37%

Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 17.07, ALGEN is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 87.21% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.30, ALGEN is valued a bit cheaper.

		Industry Rank	Sector Rank
PE	17.07
Fwd PE	N/A

4.2 Price Multiples

ALGEN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALGEN is cheaper than 89.53% of the companies in the same industry.